Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM): A Phase I Study
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 31 Oct 2019
Price : $35 *
At a glance
- Drugs Sorafenib (Primary) ; Dexamethasone; Proton pump inhibitors
- Indications Adenocarcinoma; Advanced breast cancer; Brain metastases
- Focus Adverse reactions
- 25 Oct 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2021.
- 25 Oct 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2021.
- 25 Oct 2019 Status changed from recruiting to active, no longer recruiting.